ArticleThe Biochemical journal2026
Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.
Article in The Biochemical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human antibody-based therapeutics display characteristic N-glycan profiles that are critical determinants of developability, safety, pharmacokinetics, and efficacy. Although fragment crystallizable (Fc) engineering strategies to modulate effector functions are well established, comparatively less is known about how Fc mutations designed to enhance Fc effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, influence Fc glycosylation. In the present study, we evaluated the impact of several ADC-enhancing Fc mutations (S239D/I332E, D280H/K290S, S239D/A330L/I332E, S298A/E333A/K334A, F243L/R292P/Y300L/V305I/P396L) on N-glycan composition and Fc-mediated activity. These mutations are spatially distinct from the N297 glycosylation site. Among the variants examined, antibodies containing the F243L/R292P/Y300L/V305I/P396L (LPLIL) mutations exhibited elevated levels of high-mannose glycans (Man5-9) when expressed in either CHO (Chinese hamster ovary) or HEK293 (human embryonic kidney 293) mammalian cells. Comparative glycan profiling revealed that differences in galactosylation and mannosylation between CHO- and HEK293-derived antibodies influenced CD16A binding affinity and ADCC activity across Fc variants. Notably, LPLIL-containing antibodies consistently demonstrated altered glycosylation patterns associated with enhanced effector function. Collectively, our findings demonstrated that ADCC-enhancing Fc mutations could substantially modify N-glycan composition, which in turn modulated Fc receptor engagement and downstream effector functions. These results highlighted the importance of evaluating glycosylation changes during Fc engineering to ensure optimal therapeutic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.